New drug aims to raise platelets in sepsis patients
NCT ID NCT07595133
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a drug called romiplostim in 280 sepsis patients with very low platelet counts (under 50). The drug is given as a weekly shot to try to raise platelet levels. Researchers will compare it to a standard treatment and check how well it works after 7 days, as well as survival and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- romiplostim (a platelet-boosting drug)
- What this could lead to
- If it works, this could offer a new way to quickly raise platelet counts in sepsis patients, potentially reducing bleeding risks and improving survival.
- What could go wrong
- This is a very early phase 1 trial, so the drug may not work as hoped or could cause unexpected side effects. Results may not apply to all sepsis patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we optimize antibiotic dosing for children with sepsis?
- Could starting feeds sooner shield preterm babies from infection?
- Can brain waves predict thinking problems after sepsis?
- Can tailored nutrition boost recovery in the ICU?
- Blood markers may foretell brain fog after sepsis
- A hidden clue in the fingertips: could a pulse oximeter reading forecast sepsis outcomes?